Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105524 | 0.86 | POLB (0.75) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL18965251 | 0.84 | POLB (0.64) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL24968952 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL1999759 | 0.83 | POLB (0.71) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL4907149 | 0.83 | POLB (0.71) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL12267527 | 0.82 | POLB (0.66) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL1432512 | 0.82 | KMT2A (0.72) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL3211123 | 0.82 | POLB (0.68) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL232841 | 0.82 | POLB (0.69) | SMN1; SMN2LMNAPOLBMAPTMEN1 | |
| SCHEMBL24970195 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAPOLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076585-A | Gram negative bacteria efflux pump inhibitors | 国家医疗保健研究所 | 2024-05-24 | — | — | CN | claimed |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| CN-118076585-A | Gram negative bacteria efflux pump inhibitors | 国家医疗保健研究所 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023002011-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-01-26 | — | — | WO | disclosed |
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | ACHE, AADAC, ATL3 | SMN1; SMN2 2530/4885LMNA 2586/4885POLB 4561/4885 |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ATP4B | SMN1; SMN2 4873/4885LMNA 3692/4885POLB 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.